The SLC1A3 inhibitor, (2S, 3S)‐3‐[3‐[4‐(trifluoromethyl) benzoylamino]benzyloxy] aspartate (TFB‐TBOA), inhibits cellular uptake of aspartate by cancer cells (Garcia‐Bermudez et al, 2018), and in agreement, TFB‐TBOA significantly inhibited in vitro Th17 differentiation in the presence of aspartate (Fig 4G). The gene discussed is SLC1A3; the disease is cancer.